• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 16, 2014

View Archived Issues

Pharma: Other news to note

Helsinn Group, of Lugano, Switzerland, said it granted exclusive distribution and licensing rights to Gruppo Angelini SpA, of Rome, for the commercialization in Austria, Bulgaria, Czech Republic, Hungary, Poland, Romania, Slovak Republic, Georgia, Russia and the other CIS countries of its compound in development for anorexia-cachexia syndrome related to non-small-cell lung cancer. Read More

Clinic roundup

Galectin Therapeutics Inc., of Norcross, Ga., said Providence Portland Medical Center filed an investigational new drug application on Dec. 27 to study GR-MD-02 in combination with immunotherapy Yervoy (ipilimumab, Bristol-Myers Squibb Co.) in a Phase Ib trial in patients with metastatic melanoma. Read More

Stock Movers

Read More

Other news to note

Celltrion Inc., of Incheon, South Korea, said it received approval of its cancer treatment biosimilar monoclonal antibody (mAb) Herzuma (trastuzumab), a biosimilar of Herceptin (Roche AG), from Korean regulators. Read More

Financings roundup

Cantargia AB, of Stockholm, received a capital injection of SEK3 million (US$464,000) from LU Bioscience AB, giving it a stake in Cantargia of 59.2 percent. Sven Andreasson was appointed chairman, and Lars Larsson a member of the board. Read More

Mutations in one cell type set off cancer in another

It’s an old story: Mutations lead to cancer. Except that in this case, mutations in one cell type lead to cancer in another. Read More

House passes 2014 spending bill; Senate is next

The House passed a fiscal 2014 spending bill that boosts funding for the FDA and National Institutes of Health (NIH) on a vote of 359-67 Wednesday. Read More

Nondilutive fed money predicts market success, magnet for more

SAN FRANCISCO – “Two or three years ago you would see sad faces walking around the halls of the Westin St. Francis,” said Ram May-Ron, managing partner with the Freemind Group. “Today, it’s slightly better.” Read More

Riding stock crest, Alexion looks to push the envelope

SAN FRANCISCO – Alexion Pharmaceuticals Inc. CEO Leonard Bell suggested Wednesday during his presentation at the J.P. Morgan (JPM) Healthcare Conference that the company’s investment in Moderna Therapeutics Inc. might not be its last significant business development move in 2014. Read More

Mannkind optimistic on Afrezza program despite skeptics

SAN FRANCISCO – News of the tentative April 1 advisory committee to discuss Mannkind Corp.’s resubmitted new drug application for inhaled insulin Afrezza (insulin human [rDNA origin]) powder sent the Valencia, Calif.-based firm’s shares falling 16 percent last week. Read More

RMI’s Gopka Seeks Revolutionary Science, Industry Relationships

SAN FRANCISCO – Making the move from investment banking to the world of venture capital at first sounded as though it would yield more free time and a more relaxing occupation; instead, as a managing partner at RMI Partners, Anton Gopka has found himself busier than ever, perhaps never more so than during this year’s J.P. Morgan Healthcare Conference. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe